NCT02895100Phase 2Terminated

Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis

Study sponsor: Protagonist Therapeutics, Inc. · PTGX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2018-03-26Actual

Enrollment · participants98Actual

Source updated2025-08-21Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Ulcerative Colitis

Treatments or interventions studied

PTG-100Drug
PlaceboDrug

Primary outcomes · main study measures

measure: Proportion of Subjects Receiving PTG-100 With Clinical Remission at Week 12 Compared With Placebo; description: The primary efficacy endpoint for this study was the proportion of subjects receiving PTG-100 with clinical remission at Week 12. Clinical remission was defined using the Mayo subscores of stool frequency, rectal bleeding, and endoscopy.; timeFrame: 12 week treatment period

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history